Opendata, web and dolomites

PROCROP SIGNED

Professional cross-priming for ovary and prostate cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROCROP project word cloud

Explore the words cloud of the PROCROP project. It provides you a very rough idea of what is the project "PROCROP" about.

complement    opportunity    immunity    provides    bdca    undergoing    strategy    compelling    efficacious    prostate    industrial    applies    antibody    dc    immune    mixed    managed    recombinant    dcs    autologous    proteins    destroy    expertise    culture    cytotoxic    seek    biotech    metastatic    monoclonal    malignant    rigorously    dendritic    cancer    subset    producing    accurate    efficacy    clinically    combination    endowed    antitumor    miltenyi    lymphocytes    reagents    eventual    unsatisfactorily    immunotherapy    groups    pilot    tumour    resistant    successful    material    immunomagnetic    proprietary    elicitation    castration    preparations    standardized    vaccine    isolation    therapies    clinical    permit    kill    ovary    starting    provenge    superior    join    ensuing    advantage    termed    presenting    initiated    partnership    individualized    mediated    specialised    monocytes    stronger    cells    therapy    point    multicentre    antigen    procrop    tumors    antigens    tumor    mechanism    trials    company    anti    cell    forces    minority    prevalent    suitable    view    monitoring    crosspriming    approved    presentation    processed    form    identity    fact   

Project "PROCROP" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA 

Organization address
address: AVENIDA DE PIO XII 55
city: PAMPLONA
postcode: 31008
website: www.cima.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.procrop.eu
 Total cost 7˙572˙500 €
 EC max contribution 5˙750˙000 € (76%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA ES (PAMPLONA) coordinator 1˙190˙000.00
2    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 1˙510˙000.00
3    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 1˙345˙000.00
4    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 1˙050˙000.00
5    CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) ES (MADRID) participant 655˙000.00
6    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 0.00
7    UNIVERSITE DE LAUSANNE CH (LAUSANNE) participant 0.00

Map

 Project objective

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.

 Deliverables

List of deliverables.
PROCROP Logo, graphical Chart and webpage Websites, patent fillings, videos etc. 2020-02-24 12:20:07

Take a look to the deliverables list in detail:  detailed list of PROCROP deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Arantza Azpilikueta, Elixabet Bolaños, Valerie Lang, Sara Labiano, Maria A. Aznar, Iñaki Etxeberria, Alvaro Teijeira, Maria E. Rodriguez-Ruiz, Jose L. Perez-Gracia, Maria Jure-Kunkel, Juan M. Zapata, Manuel S. Rodriguez, Ignacio Melero
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)
published pages: e1368605, ISSN: 2162-402X, DOI: 10.1080/2162402X.2017.1368605
OncoImmunology 7/1 2020-02-24
2018 Carlos del Fresno, Salvador Iborra, Paula Saz-Leal, María Martínez-López, David Sancho
Flexible Signaling of Myeloid C-Type Lectin Receptors in Immunity and Inflammation
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.00804
Frontiers in Immunology 9 2020-02-24
2018 Maria M. M. Kaisar, Manuel Ritter, Carlos del Fresno, Hulda S. Jónasdóttir, Alwin J. van der Ham, Leonard R. Pelgrom, Gabriele Schramm, Laura E. Layland, David Sancho, Clarissa Prazeres da Costa, Martin Giera, Maria Yazdanbakhsh, Bart Everts
Dectin-1/2–induced autocrine PGE2 signaling licenses dendritic cells to prime Th2 responses
published pages: e2005504, ISSN: 1545-7885, DOI: 10.1371/journal.pbio.2005504
PLOS Biology 16/4 2020-02-24
2018 Christina Wefers, Tjitske Duiveman-de Boer, Petra Zusterzeel, Leon Massuger, David Fuchs, Ruurd Torensma, Craig Wheelock, I. de Vries
Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System
published pages: 273, ISSN: 1422-0067, DOI: 10.3390/ijms19010273
International Journal of Molecular Sciences 19/1 2020-02-24
2018 Christina Wefers, Gerty Schreibelt, Leon F. A. G. Massuger, I. Jolanda M. de Vries, Ruurd Torensma
Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.01412
Frontiers in Immunology 9 2020-02-24
2017 David Sancho, Michel Enamorado, Johan Garaude
Innate Immune Function of Mitochondrial Metabolism
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2017.00527
Frontiers in Immunology 8 2020-02-24
2017 Michel Enamorado, Salvador Iborra, Elena Priego, Francisco J. Cueto, Juan A. Quintana, Sarai Martínez-Cano, Ernesto Mejías-Pérez, Mariano Esteban, Ignacio Melero, Andrés Hidalgo, David Sancho
Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells
published pages: 16073, ISSN: 2041-1723, DOI: 10.1038/ncomms16073
Nature Communications 8 2020-02-24
2017 Marcos Vasquez, Vladimir Paredes-Cervantes, Fernando Aranda, Nuria Ardaiz, Celia Gomar, Pedro Berraondo
Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.14127
Oncotarget 8/3 2020-02-24
2016 A. R. Sanchez-Paulete, F. J. Cueto, M. Martinez-Lopez, S. Labiano, A. Morales-Kastresana, M. E. Rodriguez-Ruiz, M. Jure-Kunkel, A. Azpilikueta, M. A. Aznar, J. I. Quetglas, D. Sancho, I. Melero
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
published pages: 71-79, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-15-0510
Cancer Discovery 6/1 2020-02-24
2016 Johan Garaude, Rebeca Acín-Pérez, Sarai Martínez-Cano, Michel Enamorado, Matteo Ugolini, Estanislao Nistal-Villán, Sandra Hervás-Stubbs, Pablo Pelegrín, Leif E Sander, José A Enríquez, David Sancho
Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense
published pages: 1037-1045, ISSN: 1529-2908, DOI: 10.1038/ni.3509
Nature Immunology 17/9 2020-02-24
2016 Bettina Weigelin, Elixabet Bolaños, Maria E. Rodriguez-Ruiz, Ivan Martinez-Forero, Peter Friedl, Ignacio Melero
Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
published pages: 493-497, ISSN: 0340-7004, DOI: 10.1007/s00262-016-1818-5
Cancer Immunology, Immunotherapy 65/5 2020-02-24
2016 Marcos Vasquez, Jessica Fioravanti, Fernando Aranda, Vladimir Paredes, Celia Gomar, Nuria Ardaiz, Veronica Fernandez-Ruiz, Miriam Méndez, Estanislao Nistal-Villan, Esther Larrea, Qinshan Gao, Gloria Gonzalez-Aseguinolaza, Jesus Prieto, Pedro Berraondo
Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function
published pages: e1196309, ISSN: 2162-402X, DOI: 10.1080/2162402X.2016.1196309
OncoImmunology 5/8 2020-02-24
2016 I. Melero, P. Berraondo, M. E. Rodriguez-Ruiz, J. L. Perez-Gracia
Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy
published pages: 1312-1314, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-16-1109
Cancer Discovery 6/12 2020-02-24
2017 Till S.M. Mathan, Johannes Textor, Annette E. Sköld, Inge Reinieren-Beeren, Tom van Oorschot, Mareke Brüning, Carl G. Figdor, Sonja I. Buschow, Ghaith Bakdash, I. Jolanda M. de Vries
Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.15190
Oncotarget 2020-02-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROCROP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROCROP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More